PIM1 and neuroblastoma: Similar to Brunen et al., Trigg et al. found some neuroblastoma cell lines to be PIM inhibition-resistant, leading the investigators to propose that PIM kinase inhibition alone may not be a viable treatment option in neuroblastoma, but could be employed in combination with anaplastic lymphoma kinase (ALK) inhibition [106].